For the Development of Medical Technologies.

What's New

  • 10 September, 2021We will exhibit at "Japan Healthcare Venture Summit 2021".

    Date: October 13th (Wednesday) to 15th (Friday), 2021
    Venue: Pacifico Yokohama
    (Simultaneous holding with BioJapan 2021, Regenerative Medicine JAPAN 2021 and healthTECH JAPAN 2021)
    Organizer: Ministry of Health, Labor and Welfare
    * The event may be changed to be held online depending on the infection status of the new coronavirus.

    Introducing the applied technology of solid phase transfection. We hope that the corona infection will be resolved and we will see you at the venue.

  • 10 September, 2021At the "Bio Japan / Regenerative Medicine JAPAN / healthTECH JAPAN" seminar "Drug Discovery Modality Study Group Exhibitor Presentation Drug Discovery Modality Research and Development-Fundamentals to be Prepared for 2030", our representative director Saito talks about solid-phase transfection applied research. I will make a presentation.

    Date: October 15, 2021 (Friday) 15: 00-16: 40
    Place: Pacifico Yokohama B, C, D Hall Main Stage A

    "Introduction of new peptide format STaMPtide" Kenichiro Ito (Researcher, Bio-Fine Research Institute, Ajinomoto Co., Inc.)

    "Beyond Borders-Boehringer Ingelheim Drug Discovery Research" Tomoko Maeda (Director, Drug Discovery Research Alliance, Boehringer Ingelheim Co., Ltd., Japan)

    "High affinity rabbit monoclonal antibody production service and latest results" Mr. Yoshitaku Ima (Far East Pharmaceutical Industry Co., Ltd. Antibody Business Promotion Department)

    "Buffers and columns for HPLC that contribute to mRNA therapy and RNA vaccine production" David Hild (ADSTEC Co., Ltd.)

    "Rapid and comprehensive monoclonal antibody search technology" Mr. Yo Amakusa (CEO of iBody Co., Ltd.)

    "Contributing to people's health by making full use of solid-phase transfection" Yuko Saito (CEO, CytoPathfinder, Inc.)

    "Overcoming central nervous system diseases with innovative drug delivery technology, Brain Access ?" Mr. Bunichi Kabuchi (President and CEO of Braison Therapeutics Co., Ltd.)

    "New frontiers of pathological image analysis opened up by unsupervised learning and application to companion diagnostics" Mr. Teppei Konishi (CEO of biomy Co., Ltd.)

    "Axcelead's integrated drug discovery support service and initiatives for new modality" (tentative title) Mr. Ryosuke Katsuyama (Axcelead Drug Discovery Partners Co., Ltd. Sales & Marketing)

  • 24 February, 2021We will introduce solid phase transfection technology at "virtualEXPO".

    Session: February, 2021 to Junuary, 2022
    Held: Online
    How to enter: Pre-registration from the official website
    Official website:

    We look forward to many contacts.

    What is Virtual Expo:
    VirtualExpo is an online exhibition dedicated to BtoB in the manufacturing industry from France, specializing in six fields: machinery, architecture, shipbuilding, medical care, agricultural machinery, and aviation.
    Approximately 40,000 suppliers are exhibiting, and the scale is said to be one of the largest in Europe.The number of monthly visitors is about 9.5 million, and the number of buyers is about 7.2 million.
    By exhibiting at Virtual Expo, which has more than half of European buyers, it will be possible to develop sales channels in Europe and other parts of the world.

  • 24 February, 2021We will introduce solid phase transfection technology at "BIO-EUROPE SPRING 2021".

    Session: March 22, 2021 to March 25, 2021
    Held: Online
    How to enter: Pre-registration from the official website
    Official website:

    We look forward to many contacts.

  • 10 December, 2020We will introduce solid phase transfection technology at "Biotech Showcase Digital 2021".

    Session: January 11, 2021 to January 15, 2021
    Held: Online
    How to enter: Pre-registration from the official website
    Official website:

    We look forward to many contacts.

  • 19 November, 2020We will introduce application examples of solid-phase transfection technology at the "Biotechnology for the Future" study session "Data Driven Medical Research".
    Date: December 21, 2020 (Monday)  14:00-15:30
    Seminar format: Zoom distribution (capacity 90 people)
    Organized by: Japan Bioindustry Association
    Sponsor: (Public corporation) Japan Society for Biotechnology
    Sponsored by: (Public corporation) Japan Society for Bioscience and Biotechnology (both planned)

    14:00-14:30    "Current State of Cellular Molecular Research in the Liver"
    Shuichi Kaneko (Professor, Department of Gastroenterology, Kanazawa University Hospital, Professor, Department of Medicine, Kanazawa University Pharmaceutical and Health Research Area)
    14:35-14:45    "Gene function analysis platform applying solid phase transfection technology"
    Yuko Saito (Senior Researcher, Research Department, Site Pathfinder Co., Ltd.)
    14:50-15:30    "Network-embedded drug discovery by deep learning"
    Hiroshi Tanaka (Professor Emeritus, Tokyo Medical and Dental University, Director, Institute for Next Generation Biomedical Sciences, Tohoku University Specially Appointed Professor)

    [JBA members, sponsoring / supporting group members only]
    Zoom participation:
    Deadline: Wednesday, December 16, 2020

    We look forward to your participation.

  • 18 November, 2020"Food for patients with phenylketonuria with liquid liver!"
    (Professor Nobuhiko Kojima, President, Regenerative Biology Laboratory, Yokohama City University)
    Yuko Saito donated to the project as crowd funding.

    We hope you are interested in it.

    Until November 30th.

  • 4 December, 2020We will introduce solid-phase transfection technology at the 1st showcase (seeds presentation) of the 43rd Annual Meeting of the Molecular Biology Society of Japan.
    Program No. SC-4
    Date: Friday, December 4th
    Time: 12:30 to 12:40 (presentation: 10 minutes)
    Presentation: Online by ZOOM Webinar
    Q & A, exchange meeting: Online held by Spatial Chat

    Participation would be much appreciated.

  • 13 November, 20209: 00-20: 00
    We will introduce our technology at the online exhibition "3rd Medtech Innovation Symposium & Pitch_How to Develop the World Changed by Corona-Digital Transformation of Medical Care-". Chat with participants and online meetings are possible.

    ・ Ticket sales page for online exhibition participants

    If you would like to attend the lecture, please register to attend the Zoom Webinar separately at Peatix.
    Select a webinar viewing ticket and enter the discount code "MEDIV1113".
    The discount code can be used by everyone as an invitation from the exhibitor.

    ・ Login TOP page

    ・ Online exhibitor list page

    We look forward to many contacts.

  • 14-16 October, 2020We exhibited at BioJapan 2020 held at Pacifico Yokohama. We would like to thank everyone who visited our booth.
  • July, 2020We have started joint research with the Kanazawa University Pharmaceutical Insurance Research Area Medical School.
  • April, 2020We have started joint research with the Institute for Next Generation Life Medicine, a specified non-profit organization.
  • June, 2019We have started joint work with PhoenixBio Co., Ltd. concerning in vitro siRNA transfection assay kits for human hepatocyto cells from PXB mice
  • 31 May, 2013Japan names CytoPathfinder grant recipient in two global technology collaboration support programs for FY2013
    "Prototyping and global dissemination of a human iPS cell production plate kit"
    "Prototyping and overseas sales channel development of a tool kit for supporting human miRNA functional analytical research"
  • 14 May, 2013PGXIS awarded FP7 Grant for its Taxonomy3 Analysis
  • 18 February, 2011A CytoPathfinder-Affiliated R&D Project Wins a Government Sponsorship
  • 28 October, 2010FANCL Unveils a High Performance Anti-aging Cosmetic Material Co-developed with CytoPathfinder
  • 20 August, 2010CytoPathfinder and Takeda Team Up to Expand the Horizons of a Transfection Technology
  • 29 October, 2009On 29th October 2009 the tri-party collaboration project, "Identification of off-label effects of FDA-approved drugs on aberrant splicing in myotonic dystrophy in cultured patient fibroblasts and model mice" amongst Nagoya University, Okayama University and CytoPathfinder was selected by Japan Science and Technology Agency as one of research outcome optimum incubation, A-STEP FS stage of potential pharmaceutical research.
    CytoPathfinder will contribute to further expansion of its research activities in many therapeutic areas from now on.
  • 14 August, 2009NEDO* grants subsidy to CytoPathfinder development of Cellular Pharmacogenomics (PGx) system for study on profiling of hepatotoxic compounds. (*New Energy and Industrial Technology Development Organization)
  • 13 July, 2009CytoPathfinder moves its wet lab to AIST* Tokyo Waterfront from Kiba. (*National Institute of Advanced Industrial Science and Technology)
  • 1 July, 2009CytoPathfinder begins collaboration with AIST on Cellular PGx.
  • 29 June, 2009CytoPathfinder acquired PGXIS Ltd. and its wholly-owned UK subsidiary PGXIS Ltd., a pharmacogenomic specified company.
  • 28 October, 2008Takeda Pharmaceutical; the latest recipient of CytoPathfinder's transfection technology